Post-treatment downregulation of type III interferons in patients with acute Brucellosis

Mehran Shokri, Oreinab Ghaffari Khonakdar, Mousa Mohammadnia-Afrouzi, Mahmoud Sadeghi-Haddad-Zavareh, Amirhossein Hasanpour, Mohammad Barary, Soheil Ebrahimpour
doi: https://doi.org/10.1101/2021.04.17.21255534

Article Information

doi 
https://doi.org/10.1101/2021.04.17.21255534
History 
  • April 20, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Mehran Shokri1,
  2. Oreinab Ghaffari Khonakdar2,
  3. Mousa Mohammadnia-Afrouzi3,
  4. Mahmoud Sadeghi-Haddad-Zavareh1,
  5. Amirhossein Hasanpour2,
  6. Mohammad Barary2 and
  7. Soheil Ebrahimpour1,*
  1. 1Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
  2. 2Student Research Committee, Babol University of Medical Sciences, Babol, Iran
  3. 3Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
  1. ↵*Correspondence: Soheil Ebrahimpour, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Email: drsoheil1503{at}yahoo.com. Tel: +98911-114-9309
Back to top
Posted April 20, 2021.
Download PDF
Data/Code
Email
Post-treatment downregulation of type III interferons in patients with acute Brucellosis
Mehran Shokri, Oreinab Ghaffari Khonakdar, Mousa Mohammadnia-Afrouzi, Mahmoud Sadeghi-Haddad-Zavareh, Amirhossein Hasanpour, Mohammad Barary, Soheil Ebrahimpour
medRxiv 2021.04.17.21255534; doi: https://doi.org/10.1101/2021.04.17.21255534
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area